Phase II Randomized Comparative Trial of TAK-700 (Orteronel) Versus Bicalutamide in Metastatic Prostate Cancer Patients Failing 1st Line Treatment With LHRH Agonists or Surgical Castration.
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 07 Aug 2017
Price : $35 *
At a glance
- Drugs Orteronel (Primary) ; Bicalutamide
- Indications Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 01 Jul 2014 Status changed from recruiting to discontinued,as reported by United Kingdom Clinical Research .
- 30 Jun 2014 Status changed from discontinued to withdrawn prior to enrolment as reported by ClinicalTrials.gov.